Embecta (EMBC) Cash from Financing Activities (2020 - 2026)
Embecta (EMBC) posted Cash from Financing Activities of -$41.5 million for Q1 2026, up 19.57% sequentially from -$51.6 million in Q4 2025, and down 11.26% YoY from -$46.8 million in Q1 2025.
Embecta (EMBC) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Embecta has reported Cash from Financing Activities for 7 years, with the latest figure at -$41.5 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 11.26% year-over-year to -$41.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$237.3 million (down 81.7% YoY) and the FY2025 annual result came in at -$226.7 million, down 208.86% from the prior year.
- Cash from Financing Activities grew to -$41.5 million in Q1 2026 per EMBC's latest filing, from -$51.6 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $90.3 million in Q1 2022 and troughed at -$81.6 million in Q3 2025.
- A 5-year average of -$20.9 million and a median of -$13.5 million in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities surged 179.63% in 2022, then plunged 469.7% in 2023.
- Over 5 years, Cash from Financing Activities stood at -$6.1 million in 2022, then plunged by 121.31% to -$13.5 million in 2023, then slumped by 234.81% to -$45.2 million in 2024, then fell by 14.16% to -$51.6 million in 2025, then increased by 19.57% to -$41.5 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$41.5 million, -$51.6 million, and -$81.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | -287.90 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -577.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | -510.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | -263.16 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | -159.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -300.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -75.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -31.00 Mn |
| 10 | Embecta | 305.26 Mn | 87.06 Mn | 153.30 Mn | 112.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 112.40 Mn |
| Jun 30, 2026 | 112.40 Mn |
| Mar 31, 2026 | -41.50 Mn |
| Mar 31, 2026 | -41.50 Mn |
| Dec 31, 2025 | -51.60 Mn |
| Dec 31, 2025 | -51.60 Mn |
| Sep 30, 2025 | -81.60 Mn |
| Sep 30, 2025 | -81.60 Mn |
| Jun 30, 2025 | -62.60 Mn |
| Jun 30, 2025 | -62.60 Mn |
| Mar 31, 2025 | -37.30 Mn |
| Mar 31, 2025 | -37.30 Mn |
| Dec 31, 2024 | -45.20 Mn |
| Dec 31, 2024 | -45.20 Mn |
| Sep 30, 2024 | -36.60 Mn |
| Sep 30, 2024 | -36.60 Mn |
| Jun 30, 2024 | -11.50 Mn |
| Jun 30, 2024 | -11.50 Mn |
| Mar 31, 2024 | -11.80 Mn |
| Mar 31, 2024 | -11.80 Mn |